To the Editor:

We read with interest the clinical profile of 33 children with multisystem inflammatory syndrome in children by Kaushik et al from 3 New York City tertiary care children\'s hospitals.[@bib1] There have been similar reports of a surge in children presenting with systemic inflammation, including Kawasaki-like disease from Europe and other parts of the US but not from Asia to date.[@bib2], [@bib3], [@bib4], [@bib5] We compared the epidemiologic trends in Kawasaki disease at the only public specialist children\'s hospital in Singapore before coronavirus disease-19 (COVID-19) (January 1, 2017, to December 31, 2019) and during COVID-19 (January 1, 2020, to April 30, 2020).

Since the emergence of severe acute respiratory syndrome coronavirus disease-2 (SARS-CoV-2) in Singapore, the number of cases of Kawasaki disease was lower (n = 41) compared with the average for the same period before COVID-19 (n = 56). Although cases in children 4 years of age and younger mirrored the overall lower trend, cases in children 5-9 years of age seem to be higher during COVID-19 ([Figure](#fig1){ref-type="fig"} ). In the ≥10-year-old category, there were no major variations with 1 case in 2020 vs 2 each in 2019 and 2018 and none in 2017. Comparing 2017-2019 with 2020, the mean age of patients with Kawasaki disease increased from 2.53 years to 2.80 years of age and the proportion of female cases increased from 43.9% to 51.2%. There was no significant change in average duration of hospitalization (4.9 days to 5.6 days), which may be a proxy measure of no change in Kawasaki disease case severity.FigureTemporal and age distribution of Kawasaki disease in 2020 compared with 2017-2019.

Pediatric COVID-19 cases in our hospital have been mild to moderate with no cases requiring oxygen or ventilatory support and no mortality. We have not detected a surge in Kawasaki disease cases during COVID-19 in Singapore, but noted a possible increase in age and shift in sex distribution. Close monitoring and analysis of children with systemic inflammation, especially their exposure to SARS-CoV-2 through serologic testing is warranted to evaluate whether children in Asia are at similar risk to the phenomenon reported in Europe and the US.
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